Literature DB >> 2145926

Epidermal growth factor receptor expression and suramin cytotoxicity in vitro.

S Olivier1, P Formento, J L Fischel, M C Etienne, G Milano.   

Abstract

Twenty-five cell lines derived from nine different human cancers were tested for the cytotoxic activity of suramin. Two different initial cellular concentrations were used: C1 (800-2000 cells per well) and C2 (3000-7000 cells per well). Suramin concentrations ranged from 50 to 2500 micrograms/ml. Cytotoxicity was assessed by the MTT test. Epidermal growth factor receptors (EGFR) were assayed by competition analysis and Scatchard plots. In sixteen cell lines suramin had an unexpected growth stimulation effect at low concentration (50-125 micrograms/ml). IC50 varied from 21 micrograms/ml (osteosarcoma, OS2) to 1408 micrograms/ml (melanoma, CAL 24) and, within melanoma cell lines, it varied from 120 micrograms/ml (CAL 41) to 1408 micrograms/ml (CAL 24). The individual IC50 values were positively and significantly linked with the initial cellular density. Eighteen cell lines had measurable EGFR (six with two families of sites, twelve with one): Kd varied between 0.004 nmol/l for the highest affinity site (melanoma, CAL 7) to 1.852 nmol/l for the lowest affinity site (lung, CAL 12). There was no relation between presence or absence of EGF binding sites and distribution of IC50, but for cells with measurable EGFR there was a weak but significant correlation between the number of EGF binding sites per cell and the corresponding IC50 (r = -0.53, P = 0.021).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2145926     DOI: 10.1016/0277-5379(90)90186-w

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Receptors for platelet derived growth factor in human glioma cell lines and influence of suramin on cell proliferation.

Authors:  M Westphal; E Ackermann; J Hoppe; H D Herrmann
Journal:  J Neurooncol       Date:  1991-12       Impact factor: 4.130

2.  Influence of suramin on the expression of Fc receptors and other markers on human monocytes and U937 cells, and on their phagocytic properties.

Authors:  C Schiller; A Spittler; M Willheim; Z Szépfalusi; H Agis; M Köller; M Peterlik; G Boltz-Nitulescu
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

3.  Biphasic effects of suramin on 125I-epidermal growth factor binding to human meningiomas.

Authors:  K Tsutsumi; N Kitagawa; M Niwa; S Yamaga; H Khalid; K Taniyama; A Himeno; S Shibata
Journal:  Cell Mol Neurobiol       Date:  1993-12       Impact factor: 5.046

4.  Activation of the high affinity nerve growth factor receptor by two polyanionic chemotherapeutic agents: role in drug induced neurotoxicity.

Authors:  J S Gill; A J Windebank
Journal:  J Neurooncol       Date:  1998-10       Impact factor: 4.130

5.  Suramin inhibits tumor cell cytotoxicity mediated through natural killer cells, lymphokine-activated killer cells, monocytes, and tumor necrosis factor.

Authors:  R LaPushin; K Totpal; M Higuchi; B B Aggarwal
Journal:  J Clin Immunol       Date:  1994-01       Impact factor: 8.317

Review 6.  Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.

Authors:  M M Walther; W D Figg; W M Linehan
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

7.  Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro.

Authors:  J A Foekens; A M Sieuwerts; E M Stuurman-Smeets; H A Peters; J G Klijn
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

8.  Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.

Authors:  N Magné; J L Fischel; A Dubreuil; P Formento; S Marcié; J-L Lagrange; G Milano
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

9.  Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").

Authors:  N Magné; J L Fischel; A Dubreuil; P Formento; M-F Poupon; P Laurent-Puig; G Milano
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

10.  Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.

Authors:  J-L Fischel; P Formento; G Milano
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.